Abstract: The present invention relates to the prognosticating survival of subjects with cancer. More specifically, the invention relates to methods and systems to prognosticate cancer patients by assaying RANKL, NRP-1, p-NF-kB, p-c-Met, VEGF and/or RANK expression levels and comparing those levels to reference values to determine the likelihood of survival. The present invention also provides for methods of selecting appropriate therapies for patients based on their prognosis.

Abstract: A method for interfering with osteomimetic properties of a cell includes introducing into the cell an osteomimecry-interfering compound, wherein said osteomimecry-interfering compound prevents or ameliorates the expression of the osteomimetic properties of said cell. A method for treating or ameliorating an osteotropic-related cancer or disorder in a subject includes administering to the subject an osteomimecry interfering compound. A method for identifying a compound that modulates the osteomimetic potential of a cell includes contacting a cell exhibiting osteomimetic potential with a test compound; measuring expression levels of one or more osteomimetic gene products in the cell in the presence and in the absence of the test compound; and identifying a compound that modulates the osteomimetic potential, wherein the compound changes the expression levels of one or more osteomimetic gene products in the cell.

Abstract: The present invention relates to compositions and methods for modulating osteomimicry within tumor and tissue cells with calcification potential. The invention further relates to screening compounds that modulate osteomimicry within tumor and tissue cells with calcification potential. Methods for using compounds identified by the screening assays for therapeutic treatments also are provided. The invention further relates to methods of treating those tumors and other diseases and disorders with calcification potential with compounds that modulate their osteomimetic potential.